Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 3/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL826993 | 0.83 | CES1 (0.46) | CA2CA1CA9CA5ACES1 | |
| SCHEMBL3631032 | 0.81 | CES1 (0.49) | CES1SRCMAPTTSHRCYP2C19 | |
| SCHEMBL2593896 | 0.77 | CES1 (0.44) | CA2CA1CA9CA5ACES1 | |
| SCHEMBL16339816 | 0.77 | CES1 (0.45) | CA2CA1CA9CES1SRC | |
| SCHEMBL11896557 | 0.77 | CES1 (0.45) | CES1SRCMAPTTSHRCYP2C19 | |
| SCHEMBL31159523 | 0.76 | CES1 (0.47) | CA2CA1CA9CA5ACES1 | |
| SCHEMBL13281025 | 0.76 | CES1 (0.40) | CES1SRCKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL31159402 | 0.75 | MAPT (0.47) | CA2CA1CA9CA5ACES1 | |
| SCHEMBL13280384 | 0.73 | ALDH1A1 (0.40) | CES1SRCMAPTCYP3A4TDP1 | |
| SCHEMBL12544998 | 0.73 | CES1 (0.41) | CES1SRCL3MBTL1CES2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240009153-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS, INC. | 2024-01-11 | — | — | US | disclosed |
| US-20200223854-A1 | BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-07-16 | — | — | US | disclosed |
| US-10647719-B2 | Bicyclic compounds as dual ATX/CA inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-2887806-B1 | METHOD OF TREATING AND PREVENTING BRAIN IMPAIRMENT USING NA+-K+ -2CI- COTRANSPORTER ISOFORM 1 INHIBITORS | UNIV ROCHESTER (US) | 2019-11-13 | — | — | EP | disclosed |
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2019-05-23 | — | — | US | disclosed |
| US-20180215765-A1 | NEW BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-08-02 | — | — | US | disclosed |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2017-08-31 | — | — | US | disclosed |
| US-9682928-B2 | Bumetanide analogs, compositions and methods of use | NEUROPRO THERAPEUTICS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9616075-B2 | Method of treating and preventing brain impairment using Na+-K+-2Cl-cotransporter isoform 1 inhibitors | UNIVERSITY OF ROCHESTER (US) | 2017-04-11 | — | — | US | disclosed |
| CN-105670833-A | Non-foaming low-temperature soaping agent for reactive dye and preparation method thereof | 苏州三和开泰花线织造有限公司 | 2016-06-15 | — | — | CN | disclosed |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS INC. | 2015-03-19 | — | — | US | disclosed |
| WO-2014014519-A1 | METHOD OF TREATING AND PREVENTING BRAIN IMPAIRMENT USING NA+-K+ -2CI- COTRANSPORTER ISOFORM 1 INHIBITORS | UNIVERSITY OF ROCHESTER (US) | 2014-01-23 | — | — | WO | disclosed |
| EP-2598478-A2 | ARYLSULFONAMIDE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | Neurotherapeutics Pharma, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2013059648-A1 | 2,3,5 TRISUBSTITUTED ARYL AND HETEROARYL AMINO DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2012018635-A2 | ARYLSULFONAMIDE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20120004225-A1 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| EP-2389371-A2 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | Neurotherapeutics Pharma, Inc. (US) | 2011-11-30 | — | — | EP | disclosed |
| WO-2010085352-A2 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2010-07-29 | — | — | WO | disclosed |
| WO-2006011719-A1 | N-SUBSTITUTED-SULFAMOYLBENZOIC ACID DERIVATIVES, METHOD FOR PREPARING THEREOF AND ANTIVIRAL PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | B & C BIOPHARM CO., LTD. (KR) | 2006-02-02 | — | — | WO | disclosed |
| US-4161531-A | Diuretic and saluretic 5-sulfamoylbenzoic acid derivatives carrying a heterocyclic substituent | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200223854-A1 | BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | ATXN2, ATXN2L, ATXN10 | CA2 238/4885CA1 1155/4885CA9 1224/4885 |
| US-20240009153-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | CA2 489/4885CA1 988/4885CA9 743/4885 |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | CA2 471/4885CA1 1022/4885CA9 710/4885 |
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A11, SLC6A13 | CA2 388/4885CA1 701/4885CA9 641/4885 |
| US-20120004225-A1 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | ABCG2, ABCB1, TRPV1 | CA2 1572/4885CA1 1755/4885CA9 1396/4885 |
| US-20180215765-A1 | NEW BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | ATXN2, ATXN2L, ATXN10 | CA2 473/4885CA1 1536/4885CA9 1774/4885 |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | CA2 1422/4885CA1 1762/4885CA9 1040/4885 |
| US-10647719-B2 | Bicyclic compounds as dual ATX/CA inhibitors | ATXN2, ATXN2L, ATXN10 | CA2 238/4885CA1 1155/4885CA9 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.